RE: Who knows ?29 Jul 2020 17:15
Botski / Bermuda ,
I think this is the paragraph you wanted to see Bermuda -
The Company has entered into three non-exclusive research agreements with leading antibody technology companies in Europe, the USA and China to evaluate the Company's anti-TaG mAbs including those enhanced with the AvidiMab™ technology. TaGs can be targeted by several other tumour cell killing approaches, including antibody drug conjugates (ADC), redirected T-cells, and also adoptive cell therapies such as chimeric antigen receptor (CAR) T cells. Under the terms of the collaboration and research agreements, Scancell and its partners will evaluate the potential of the anti-TaG mAbs, in these various formats. The Company expects these collaboration and research agreements could transition into potential partnerships. Advanced commercial discussions are currently underway with a global biotech with initial commercial collaboration potentially to be in the form of granting a partner an option to a future licence.
The important bit for me is “ advanced commercial discussions “ not advanced scientific discussions .
We will all read differently I’m sure but for me it reads that money is involved ,maybe in the form of upfront or outright or however .